Every Form 4 that Processa Pharmaceuticals, Inc. Common (PCSA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PCSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCSA filings page.
Processa Pharmaceuticals, Inc. director and CEO George K. Ng reported the distribution of a time-based restricted stock award. On August 8, 2026, 1,600 shares of restricted stock converted into 1,600 shares of common stock, leaving him with 17,092 directly held common shares and 19,624 restricted shares. He also reports options to acquire 30,720 common shares at an exercise price of $4.96 per share and additional indirect common stock holdings through related entities. Certain reported share amounts reflect a 1-for-25 reverse stock split effective December 17, 2025.
Processa Pharmaceuticals, Inc. director Sheila Gujrathi reported acquiring Series A Non-Voting Convertible Preferred Stock on July 28, 2026, in connection with the acquisition of Vidya Therapeutics, Inc. She received 70,811.877 Series A Preferred shares held directly.
An additional 12,311.279 Series A Preferred shares are held indirectly by SilverArc Private Fund I, L.P., an investment fund with which she is associated; she disclaims beneficial ownership except for any pecuniary interest. The Series A Preferred has no expiration and, subject to conditions, each share is convertible into 1,000 shares of Processa common stock.
Processa Pharmaceuticals, Inc. director Justin W. Yorke received a grant of 33,500 Restricted Stock Units (RSUs) on July 26, 2026. Each RSU represents a contingent right to one share of common stock and vested upon grant, with distribution deferred until the earlier of termination, six months after grant, a change of control, or death. Following this grant, he holds 38,749 RSUs, stock options for 12,000 shares at an exercise price of $4.96, and common stock totaling 353 shares directly plus additional indirect holdings, all reflecting a 1-for-25 reverse stock split effected on December 17, 2025.
Processa Pharmaceuticals, Inc. reported that Chief Financial Officer Russell Skibsted received a grant of 11,883 Restricted Stock Units on July 26, 2026. These RSUs vested immediately but will be settled later under specified conditions. After the grant he directly holds 17,323 RSUs, 16,689 common shares and stock options over 12,960 shares at a $4.9600 exercise price.
Processa Pharmaceuticals director Geraldine Pannu received a grant of 33,500 Restricted Stock Units on July 26, 2026. Each RSU equals one share of common stock, vested upon grant, and will be settled at the earlier of termination, six months after grant, change of control, or death.
After this award she reports direct holdings of 38,749 RSUs, stock options for 12,000 shares at an exercise price of $4.9600, and 2,391 common shares. Reported amounts reflect the company’s 1-for-25 reverse stock split effective December 17, 2025.
Processa Pharmaceuticals, Inc. granted Chief Executive Officer George K. Ng 9,384 Restricted Stock Units on July 26, 2026. Each RSU equals one common share, vested immediately, with settlement deferred until termination, six months after grant, a change of control, or death.
After this award, Ng directly holds 21,224 RSUs, stock options for 30,720 shares at an exercise price of $4.96 per share, and additional direct and indirect common stock holdings; all reported share amounts reflect a 1-for-25 reverse stock split effected on December 17, 2025.
Neal James R reported acquisition or exercise transactions in this Form 4 filing.
Processa Pharmaceuticals, Inc. director Neal James R received a grant of 62,221 Restricted Stock Units (RSUs) on July 26, 2026, each representing one share of common stock. The RSUs vested upon grant but will be distributed only upon termination, six months after grant, a change of control, or death. Following this award, he holds 67,470 RSUs, stock options for 12,000 shares at $4.96 vesting over three years, and 1,021 common shares, all on a direct-ownership basis. Reported amounts reflect a 1-for-25 reverse stock split effective December 17, 2025.
Processa Pharmaceuticals, Inc. officer Patrick Lin received a grant of 8,450 Restricted Stock Units on 2026-07-26. Each RSU equals one share of common stock, vesting upon grant but distributed only at the earlier of termination, six months after grant, a change of control, or death. Following this award, he holds 11,389 RSUs, stock options over 8,160 shares at an exercise price of $4.9600 that vest over three years, and common stock holdings of 13,113 shares directly plus 1,740 shares indirectly through the Lin Family Trust. These amounts reflect a 1-for-25 reverse stock split effective December 17, 2025, and were not reported as made under a Rule 10b5-1 trading plan.
Processa Pharmaceuticals, Inc. reported that Chief Administrative Officer Wendy Guy received a grant of 9,450 Restricted Stock Units on 2026-07-26, each representing one share of common stock. These RSUs vested on grant but will be delivered in shares at the earlier of termination, six months after grant, a change of control, or death.
After this award, Guy holds 11,669 RSUs directly, stock options for 6,000 shares at an exercise price of $4.9600 vesting over three years, 14,394 shares of common stock directly, and 333 shares indirectly through CorLyst, LLC.
Baluch Khoso reported acquisition or exercise transactions in this Form 4 filing.
Processa Pharmaceuticals, Inc. director Baluch Khoso received a grant of 33,500 Restricted Stock Units on 26 July 2026, each representing one share of common stock. The RSUs vested immediately but will be distributed only upon termination, six months after grant, a change of control, or death. Following this award, Khoso holds 38,749 RSUs, 12,000 stock options to buy common shares at $4.96, and 2,528 common shares directly, all reflecting a 1-for-25 reverse stock split completed in December 2025.
Processa Pharmaceuticals insider activity: Chief Administrative Officer Guy Wendy bought 2,436 shares of common stock in an open-market purchase at $1.93 per share. After this trade, she holds 14,394 shares directly and 333 shares indirectly through CorLyst, LLC.
Processa Pharmaceuticals, Inc. executive Patrick Lin, Chief Business-Strategy Officer, bought additional common stock in the company. On June 30, 2026, he made an open-market purchase of 2,106 shares at $1.93 per share.
After this transaction, Lin directly holds 13,113 common shares. The filing also lists an indirect holding of 1,740 shares registered under the Lin Family Trust dated February 4, 2024, giving investors a clearer view of both his direct and trust-related ownership.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought 3,057 shares of Common Stock in an open-market purchase at $1.93 per share on July 1, 2026. After this trade, he directly owns 15,492 shares, plus additional indirect holdings through related entities.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of 3,277 shares of Common Stock at $1.93 per share. After this transaction, he directly owns 16,689 shares. This filing reflects a relatively small insider buy by a senior executive.
Processa Pharmaceuticals, Inc. director and officer David Young bought additional common stock in an open-market transaction. On June 30, 2026, he purchased 2,531 shares at $1.93 per share, bringing his direct holdings to 21,729 shares of common stock.
He also reports indirect ownership of common stock through several entities as of that date: 1,009 shares held by CorLyst, LLC, 432 shares held by Family Entities, and 1,242 shares held by the Young-Plaisance Revocable Trust.
Processa Pharmaceuticals director Justin W. Yorke reported a routine equity compensation event. On June 26, 2026, he exercised a time-based service restricted stock award, converting 203 restricted shares into 203 shares of common stock at $0.00 per share.
After the transaction, Yorke holds 353 common shares directly, plus 496 common shares held indirectly through a directed trust IRA and 1,250 common shares held indirectly via Richland Fund, LLC. He also continues to hold 5,249 restricted stock units directly.
Processa Pharmaceuticals director Geraldine Pannu reported a routine equity compensation event. She exercised a derivative award relating to 203 shares of Common Stock on June 26, 2026, at a stated exercise price of $0.00 per share, tied to a time-based service award.
Following the transaction, her direct holdings of Common Stock increased to 2,391 shares. The related Restricted Stock position, which served as the derivative security, showed 5,249 units following the exercise. The filing characterizes this as an exercise or conversion of a derivative security, reflecting compensation rather than an open-market trade.
Processa Pharmaceuticals director Neal James R reported a compensation-related share vesting. On June 26, 2026, he exercised a time-based service award, converting 203 shares of restricted stock into 203 shares of common stock at a stated price of $0.00 per share.
After the transaction, he directly holds 1,021 shares of common stock and 5,249 shares of restricted stock. The filing shows an exercise of a derivative security rather than any open-market purchase or sale of Processa Pharmaceuticals stock.
Processa Pharmaceuticals director Baluch Khoso reported a small equity compensation event. On June 26, 2026, Khoso exercised a time-based service award, converting 203 shares of Restricted Stock into 203 shares of Common Stock at an exercise price of $0.00 per share.
After the transaction, Khoso directly held 2,528 shares of Common Stock and 5,249 shares of Restricted Stock, reflecting a routine distribution of equity granted for service rather than an open-market purchase or sale.
Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of common stock. He bought 2,067 shares on June 15, 2026 at $2.22 per share, bringing his directly held position to 19,198 shares of Processa Pharmaceuticals common stock.
In addition to these directly owned shares, he is also reported as having indirect ownership of 1,009 shares through CorLyst, LLC, 432 shares through Family Entities, and 1,242 shares through the Young-Plaisance Revocable Trust as of the same date.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company stock. On this transaction date, he bought 2,654 shares of common stock at a price of $2.22 per share. Following the purchase, his direct holdings increased to 13,412 shares of common stock.
Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,465 shares of Common Stock at $2.22 per share. Following this trade, his directly held Common Stock position increased to 12,435 shares.
Ng also reports indirect ownership of Common Stock, including 800 shares held through the Ng Cha Family Trust and 3,488 shares held through an account labeled George Ng IRRA FOB George Ng.
Processa Pharmaceuticals Chief Business - Strategy Officer Patrick Lin bought 1,831 shares of Common Stock in an open-market transaction at $2.22 per share. Following this purchase, he directly owns 11,007 shares and reports 1,740 shares held indirectly through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals, Inc. Chief Administrative Officer Wendy Guy reported an open-market purchase of 2,118 shares of common stock at $2.22 per share on June 15, 2026. After this transaction, Guy directly holds 11,958 common shares and has an additional 333 shares reported as indirectly owned through CorLyst, LLC.
Processa Pharmaceuticals, Inc. director and President of Research & Development David Young reported an open-market purchase of 1,786 shares of common stock at $2.57 per share on May 29, 2026. Following this transaction, he directly holds 17,131 common shares.
The filing also lists indirect holdings of common stock, including 742 shares held through CorLyst, LLC, 432 shares held through family entities, and 1,242 shares held through the Young-Plaisance Revocable Trust as of the same date.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of Common Stock. On May 29, 2026, he bought 2,292 shares at $2.57 per share, bringing his directly held position to 10,758 shares after the transaction.
Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,129 shares of Common Stock at $2.57 per share on May 29, 2026. Following this transaction, his direct holdings increased to 9,970 Common Stock shares.
The filing also lists indirect ownership positions of 800 Common Stock shares held through the Ng Cha Family Trust and 3,488 Common Stock shares held through an account labeled George Ng IRRA FOB George Ng, reflecting additional indirect exposure to Processa shares.
Processa Pharmaceuticals Chief Business-Strategy Officer Patrick Lin bought additional company stock. On an open-market purchase, he acquired 1,582 shares of common stock at $2.57 per share. After this trade, he directly owns 9,176 shares. A separate holding entry shows 1,740 shares held indirectly through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy reported an open-market purchase of 1,829 shares of Common Stock at $2.57 per share. After this trade, she directly owns 9,840 shares and is also shown with 333 shares held indirectly through CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng reported buying 1,843 shares of common stock in an open-market transaction at $2.97 per share. Following this purchase, he holds 7,841 shares directly.
The filing also shows indirect holdings of 800 shares through the Ng Cha Family Trust and 3,488 shares through an account labeled George Ng IRRA FOB George Ng. A footnote notes an immaterial correction to a prior Form 4, adjusting an April 30, 2026 purchase to $2.71 per share and reducing that earlier trade by 15 shares.
Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of 1,545 shares of common stock at $2.97 per share on May 15, 2026. After this trade, he directly holds 15,345 common shares.
The filing also reports indirect holdings of 742 shares through CorLyst, LLC, 432 shares through family entities, and 1,242 shares through the Young-Plaisance Revocable Trust as of the same date. A footnote states that share amounts were adjusted to correct immaterial errors in a prior Form 4, including a corrected April 30, 2026 purchase price of $2.71 per share instead of $2.69, which reduced that earlier purchase by 13 shares.
Processa Pharmaceuticals, Inc. Chief Business - Strategy Officer Patrick Lin reported an open-market purchase of 1,369 shares of common stock at $2.97 per share. Following this transaction, he directly owns 7,594 shares and indirectly holds 1,740 shares through the Lin Family Trust dated February 4, 2024.
A footnote states that share figures were adjusted to correct immaterial errors in a prior Form 4. The corrected price per share for a purchase on April 30, 2026 is $2.71 instead of $2.69, which reduced that earlier purchase by 11 shares.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy reported an open-market purchase of 1,583 shares of common stock at $2.97 per share. After this trade, she directly holds 8,011 shares and is also shown with 333 shares held indirectly through CorLyst, LLC.
The filing also corrects earlier data, noting that a purchase on April 30, 2026 was executed at $2.71 per share instead of $2.69, which reduces that earlier purchase by 13 shares. This adjustment is described as correcting immaterial errors in a prior Form 4.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of the company’s Common Stock. On May 15, he bought 1,984 shares at $2.97 per share, bringing his direct holdings to 8,466 shares.
The filing also notes that share totals were adjusted to correct immaterial errors in a prior Form 4. The corrected price for a purchase on April 30 is stated as $2.71 instead of $2.69, which reduced that earlier purchase by 16 shares.
Processa Pharmaceuticals Chief Executive Officer George K. Ng reported an open-market purchase of 1,843 shares of Common Stock at $2.97 per share. After this transaction, his directly held Common Stock position reported in this filing increased to 3,979 shares.
The filing also lists indirect holdings of 800 shares held by the Ng Cha Family Trust and 3,488 shares held by an account identified as George Ng IRRA FOB George Ng as of the same date.
Processa Pharmaceuticals, Inc. Chief Development Officer Sian Bigora reported an open-market purchase of 1,971 shares of common stock at $2.71 per share. Following this transaction, she directly holds 7,481 shares of common stock.
The filing also reports 267 shares of common stock held indirectly through CorLyst, LLC. A footnote states that shares were adjusted to correct immaterial errors, indicating minor corrections to previously reported share amounts.
Processa Pharmaceuticals director and executive David Young reported buying additional common stock. On April 30, 2026, he made an open-market purchase of 1,706 shares at $2.69 per share, bringing his direct holdings to 13,813 shares. He also reports indirect ownership of 742 shares through CorLyst, LLC, 432 shares through family entities, and 1,242 shares through the Young-Plaisance Revocable Trust.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted made an open-market purchase of the company’s Common Stock. On the reported date, he bought 2,190 shares at a price of $2.69 per share and, after this transaction, directly held a total of 6,498 shares.
Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,034 shares of Common Stock at $2.69 per share. This buy increased his direct ownership to 6,013 shares of Common Stock.
As of the transaction date, he also reported indirect ownership of 800 shares held by the Ng Cha Family Trust and 3,488 shares held under "George Ng IRRA FOB George Ng." All holdings reflect positions as of April 30, 2026.
Processa Pharmaceuticals Chief Business-Strategy Officer Patrick Lin bought 1,511 shares of common stock in an open-market purchase at $2.69 per share. After this transaction, he directly owns 6,236 shares and indirectly holds 1,740 shares through the Lin Family Trust Feb 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy reported an open-market purchase of the company’s common stock. On April 30, 2026, she bought 1,748 shares of Processa Pharmaceuticals, Inc. common stock at $2.69 per share in a direct transaction.
Following this purchase, she directly owns 6,441 common shares. The filing also lists an indirect holding of 333 common shares described as held "By CorLyst, LLC," reflecting a separate ownership line associated with her.
Processa Pharmaceuticals Chief Development Officer buys shares on the open market. Reporting person Sian Bigora acquired 1,986 shares of Processa Pharmaceuticals common stock in an open-market purchase at $2.69 per share, bringing direct holdings to 7,496 shares. The filing also shows 267 shares of common stock held indirectly through CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng reported an open-market purchase of common stock. On April 15, 2026, he bought 1,843 shares of Processa common stock at $2.97 per share, bringing his directly held stake to 3,979 shares.
The filing also shows indirect holdings of 800 shares held through the Ng Cha Family Trust and 3,488 shares held through an account identified as George Ng IRRA FOB George Ng. These lines reflect ownership positions rather than new transactions.
Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,136 shares of common stock at $2.535 per share. After this transaction, he directly holds 2,136 shares. He also reports indirect ownership of 800 shares through the Ng Cha Family Trust and 3,488 shares through an account labeled George Ng IRRA FOB George Ng.
Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of 1,545 shares of common stock at $2.97 per share on April 15, 2026. After this trade, he holds 12,107 shares directly, plus indirect holdings of 1,242 shares via the Young-Plaisance Revocable Trust, 432 shares via family entities, and 742 shares via CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought additional company stock in the open market. He purchased 1,843 shares of common stock at $2.97 per share, bringing his directly held position to 5,492 shares. The filing also lists indirect holdings of 3,488 shares held under "George Ng IRRA FOB George Ng" and 800 shares held through the "Ng Cha Family Trust," showing both personal and related-entity ownership of Processa common stock.
Processa Pharmaceuticals, Inc. Chief Business - Strategy Officer Patrick Lin bought common stock in the open market. On April 15, 2026, he purchased 1,369 shares of Processa common stock at $2.97 per share. After this transaction, he directly holds 4,725 shares and indirectly holds 1,740 shares through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy purchased 1,583 shares of common stock in an open-market transaction at $2.97 per share. After this purchase, she holds 4,693 shares directly and 333 shares indirectly through CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Development Officer Sian Bigora reported an open-market purchase of 1,799 shares of common stock at $2.97 per share on April 15, 2026. Following this trade, Bigora directly holds 5,510 common shares and has indirect ownership of 267 shares through CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company shares. On April 15, 2026, he bought 1,984 shares of Common Stock at $2.97 per share in a direct ownership transaction, bringing his directly held stake to 4,308 shares.